dr. taylor discusses the toxicities and impact of lenvatinib in the select trial
Published 8 years ago • 72 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
2:07
dr. wirth discusses the safety profile of lenvatinib as seen in the select trial
-
3:37
dr. wirth discusses the results of the select trial in thyroid cancer
-
1:59
effect of age and lenvatinib treatment on os for patients with thyroid cancer
-
1:23
dr. brose discusses lenvatinib for the treatment of patients with thyroid cancer
-
20:02
management of differentiated thyroid carcinoma in the era of targeted therapy
-
3:56
lenvatinib: exploring dose reductions and interruptions
-
6:42
treatment choices in thyroid cancer
-
1:02
dr. keith c. bible on treatments beyond the first-line in thyroid cancer
-
1:10
dr. marcia brose on lenvatinib in differentiated thyroid cancer
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
10:32
advancements in targeted therapies: new hope for advanced thyroid cancer patients
-
1:00:38
medullary thyroid cancer & new therapies with dr. elisei
-
45:54
molecular classification of endometrial cancer and targeted therapy considerations
-
54:31
targeted therapies advanced differentiated thyroid cancer with dr. gianoukakis
-
57:15
212 drugs in development for rai-refractory differentiated thyroid cancer. new molecular targets
-
17:51
author interview - professor taylor
-
2:06
a seat at the table: removing barriers and bias for women in oncology
-
1:03:08
anaplastic thyroid cancer with dr. nancy lee